Biocept has announced the commercial availability of its Target Selector pan-TRK assay  for the detection of TRK proteins. With the test, a blood sample can identify the potential presence of NTRK fusions—actionable biomarkers that can be used to qualify patients for treatment with TRK inhibitor therapies. With the launch of this new assay, Biocept now offers 20 CLIA-certified liquid biopsy tests utilizing its Target Selector platform to determine the status of actionable solid tumor biomarkers.

For qualified patients with NTRK fusions, there are currently two approved first-generation TRK inhibitor therapies on the market, Vitrakvi (larotrectinib) and Rozlytrek (entrectinib). Biocept’s Target Selector pan-TRK assay is a liquid biopsy test designed to detect NTRK antibodies from a patient’s blood sample. Sensitivity and specificity between the presence of TRK proteins and FISH detection of NTRK fusions is 95.2% and 100%, respectively. This indicates that the pan-TRK assay can be used as a simple and cost-effective method for determining the potential presence of NTRK fusions and whether further testing is advised.